The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...

“We understand patients experience MG and CIDP in different ways, and our prefilled syringe is an important innovation that provides patients with more freedom and flexibility to self-administer ...

(RTTNews) - Halozyme Therapeutics Inc. (HALO) announced that argenx has received U.S. Food and Drug Administration approval of VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod ...

The U.S. regulator has signed off on argenx’s prefilled syringe (PFS) version of Vyvgart Hytrulo, which allows patients to self-inject at home as opposed to undergoing infusions or making weekly ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

SMi Group will focus on patient needs in parenteral drug delivery in an exclusive spotlight at the 10 th annual Pre-Filled Syringes Europe conference and exhibition when it returns to Central ...